sotyktu for psoriasis
sotyktu for psoriasis (2)
sotyktu for psoriasis (3)
sotyktu for psoriasis
sotyktu for psoriasis (2)
sotyktu for psoriasis (3)

Sotyktu

Sotyktu (deucravacitinib) is an oral medication used to treat moderate to severe plaque psoriasis by selectively targeting the TYK2 pathway, which plays a key role in driving psoriasis-related inflammation.
Rinvoq is an oral Janus kinase (JAK) inhibitor that reduces inflammation and helps manage moderate to severe plaque psoriasis.
It is ideal for individuals with moderate to severe psoriasis who have not responded to other systemic treatments or biologics.
Improvements are typically seen within 2–4 weeks of starting treatment.
This treatment is prescribed for adults with moderate to severe plaque psoriasis who need systemic therapy. It is taken as a once-daily oral tablet and offers a non-injectable option for long-term disease control. See pricing details here.

Real patients, real results

How effective is Sotyktu

Clinically proven results

Clearer skin and reduced plaque severity with consistent daily use.*
Clinical trials show that Sotyktu significantly improves psoriasis symptoms, including redness, scaling, and plaque thickness, by precisely controlling immune overactivity.
*Improvement is commonly seen within 12–16 weeks of continued treatment.
Sotyktu should be used only as prescribed by a healthcare provider. For more information, see Important Safety Information.

How DermOnDemand Works

Common Question

Common side effects include headache, nausea, and upper respiratory infections. Rarely, it may increase the risk of blood clots or serious infections.
Yes, blood tests may be needed to monitor for potential side effects like liver function changes or anemia.